| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Denmark | 93 | 2022 | 2654 | 2.84 | Why? |
| Heart Failure | 65 | 2021 | 6638 | 2.71 | Why? |
| Heart Failure, Systolic | 5 | 2019 | 39 | 2.02 | Why? |
| Stroke Volume | 29 | 2019 | 2153 | 1.80 | Why? |
| Defibrillators, Implantable | 13 | 2019 | 624 | 1.78 | Why? |
| Out-of-Hospital Cardiac Arrest | 19 | 2019 | 1047 | 1.53 | Why? |
| Percutaneous Coronary Intervention | 21 | 2019 | 3646 | 1.48 | Why? |
| Myocardial Perfusion Imaging | 4 | 2019 | 218 | 1.39 | Why? |
| ST Elevation Myocardial Infarction | 19 | 2019 | 3051 | 1.39 | Why? |
| Atrial Fibrillation | 19 | 2021 | 2320 | 1.33 | Why? |
| Myocardial Infarction | 20 | 2021 | 3361 | 1.31 | Why? |
| Enalapril | 4 | 2018 | 54 | 1.07 | Why? |
| Electric Countershock | 8 | 2018 | 284 | 1.02 | Why? |
| Peptide Fragments | 9 | 2019 | 2075 | 0.98 | Why? |
| Adrenergic beta-Antagonists | 12 | 2019 | 465 | 0.97 | Why? |
| Pacemaker, Artificial | 5 | 2019 | 431 | 0.96 | Why? |
| Myocardial Ischemia | 8 | 2021 | 781 | 0.93 | Why? |
| Coronary Artery Disease | 13 | 2019 | 2570 | 0.93 | Why? |
| Heart Conduction System | 5 | 2018 | 266 | 0.90 | Why? |
| Tetrazoles | 7 | 2019 | 262 | 0.89 | Why? |
| Cardiac Pacing, Artificial | 2 | 2019 | 160 | 0.85 | Why? |
| Fumarates | 4 | 2019 | 38 | 0.85 | Why? |
| Death, Sudden, Cardiac | 8 | 2019 | 522 | 0.83 | Why? |
| Registries | 48 | 2021 | 12327 | 0.82 | Why? |
| Natriuretic Peptide, Brain | 8 | 2019 | 1215 | 0.82 | Why? |
| Ventricular Function, Left | 15 | 2019 | 1555 | 0.81 | Why? |
| Lactic Acid | 2 | 2020 | 393 | 0.78 | Why? |
| Endocarditis, Bacterial | 6 | 2019 | 344 | 0.77 | Why? |
| Cardiopulmonary Resuscitation | 12 | 2019 | 1876 | 0.74 | Why? |
| Endocarditis | 6 | 2019 | 368 | 0.74 | Why? |
| Positron Emission Tomography Computed Tomography | 2 | 2019 | 1458 | 0.72 | Why? |
| Shock, Cardiogenic | 3 | 2020 | 700 | 0.70 | Why? |
| Proportional Hazards Models | 30 | 2020 | 6543 | 0.67 | Why? |
| Protein Precursors | 2 | 2018 | 425 | 0.67 | Why? |
| Coronary Circulation | 5 | 2019 | 188 | 0.65 | Why? |
| Heart Ventricles | 4 | 2019 | 1139 | 0.64 | Why? |
| Diabetes Mellitus, Type 2 | 11 | 2019 | 6166 | 0.62 | Why? |
| Ischemic Attack, Transient | 1 | 2020 | 439 | 0.62 | Why? |
| Bundle-Branch Block | 2 | 2019 | 127 | 0.60 | Why? |
| Ventricular Dysfunction, Left | 6 | 2018 | 993 | 0.60 | Why? |
| Adrenomedullin | 1 | 2018 | 217 | 0.60 | Why? |
| Risk Assessment | 35 | 2021 | 25439 | 0.59 | Why? |
| Stroke | 15 | 2021 | 8839 | 0.59 | Why? |
| Electrocardiography | 13 | 2019 | 3957 | 0.58 | Why? |
| Rubidium Radioisotopes | 3 | 2019 | 12 | 0.58 | Why? |
| Aged | 139 | 2021 | 215776 | 0.54 | Why? |
| Myocardial Revascularization | 5 | 2019 | 267 | 0.52 | Why? |
| Biphenyl Compounds | 7 | 2019 | 249 | 0.52 | Why? |
| Middle Aged | 144 | 2021 | 270681 | 0.51 | Why? |
| Cardiovascular Diseases | 19 | 2022 | 11497 | 0.51 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 17 | 2020 | 5277 | 0.51 | Why? |
| Aminobutyrates | 4 | 2018 | 142 | 0.50 | Why? |
| Diabetic Angiopathies | 3 | 2019 | 146 | 0.49 | Why? |
| Myotonic Dystrophy | 1 | 2012 | 51 | 0.48 | Why? |
| Follow-Up Studies | 33 | 2021 | 17020 | 0.48 | Why? |
| Hypokalemia | 4 | 2018 | 195 | 0.47 | Why? |
| Prognosis | 45 | 2020 | 32490 | 0.47 | Why? |
| Receptors, Urokinase Plasminogen Activator | 3 | 2019 | 252 | 0.46 | Why? |
| Female | 160 | 2021 | 380317 | 0.46 | Why? |
| Male | 158 | 2021 | 367725 | 0.46 | Why? |
| Coronary Artery Bypass | 4 | 2019 | 629 | 0.45 | Why? |
| Incidence | 36 | 2021 | 25622 | 0.45 | Why? |
| Risk Factors | 73 | 2021 | 71621 | 0.45 | Why? |
| Time Factors | 45 | 2020 | 31397 | 0.45 | Why? |
| Angiotensin Receptor Antagonists | 11 | 2020 | 3892 | 0.44 | Why? |
| Mortality | 10 | 2020 | 7132 | 0.44 | Why? |
| Coma | 3 | 2018 | 204 | 0.43 | Why? |
| Potassium | 3 | 2018 | 325 | 0.43 | Why? |
| Hypertrophy, Left Ventricular | 3 | 2018 | 219 | 0.42 | Why? |
| Acute Coronary Syndrome | 3 | 2020 | 2107 | 0.40 | Why? |
| Aged, 80 and over | 65 | 2021 | 88759 | 0.40 | Why? |
| Aortic Valve Stenosis | 4 | 2018 | 741 | 0.39 | Why? |
| Cardiac Resynchronization Therapy | 4 | 2019 | 191 | 0.39 | Why? |
| Predictive Value of Tests | 20 | 2019 | 9537 | 0.39 | Why? |
| Warfarin | 3 | 2019 | 402 | 0.39 | Why? |
| Heart Valve Prosthesis Implantation | 4 | 2019 | 552 | 0.38 | Why? |
| Defibrillators | 3 | 2018 | 144 | 0.38 | Why? |
| Amides | 4 | 2019 | 1864 | 0.37 | Why? |
| Humans | 190 | 2022 | 930598 | 0.35 | Why? |
| Multivariate Analysis | 15 | 2020 | 5440 | 0.35 | Why? |
| Cause of Death | 16 | 2018 | 4823 | 0.35 | Why? |
| Propanolamines | 3 | 2017 | 47 | 0.35 | Why? |
| Survival Rate | 20 | 2019 | 9206 | 0.35 | Why? |
| Fractional Flow Reserve, Myocardial | 3 | 2019 | 173 | 0.34 | Why? |
| Electrocardiography, Ambulatory | 3 | 2017 | 204 | 0.33 | Why? |
| Ischemic Postconditioning | 2 | 2017 | 13 | 0.32 | Why? |
| Heart Diseases | 5 | 2019 | 3503 | 0.32 | Why? |
| Dabigatran | 2 | 2019 | 204 | 0.32 | Why? |
| Valsartan | 5 | 2018 | 206 | 0.32 | Why? |
| Hypoxia, Brain | 2 | 2017 | 92 | 0.32 | Why? |
| Treatment Outcome | 39 | 2019 | 51732 | 0.32 | Why? |
| Diabetes Mellitus | 7 | 2021 | 8207 | 0.32 | Why? |
| Doxorubicin | 2 | 2018 | 313 | 0.31 | Why? |
| Magnetic Resonance Imaging, Cine | 4 | 2019 | 669 | 0.31 | Why? |
| Myocardium | 5 | 2019 | 2323 | 0.31 | Why? |
| Postoperative Hemorrhage | 2 | 2018 | 183 | 0.31 | Why? |
| Echocardiography | 7 | 2019 | 3661 | 0.30 | Why? |
| Hypothermia, Induced | 2 | 2018 | 176 | 0.30 | Why? |
| Myocardial Reperfusion Injury | 2 | 2018 | 129 | 0.30 | Why? |
| Benzimidazoles | 2 | 2019 | 275 | 0.30 | Why? |
| Hospitalization | 27 | 2021 | 54280 | 0.30 | Why? |
| Mineralocorticoid Receptor Antagonists | 4 | 2019 | 203 | 0.30 | Why? |
| Double-Blind Method | 12 | 2019 | 5988 | 0.29 | Why? |
| Thromboembolism | 4 | 2018 | 2101 | 0.29 | Why? |
| Rivaroxaban | 2 | 2019 | 467 | 0.28 | Why? |
| Coronary Vessels | 5 | 2018 | 914 | 0.28 | Why? |
| Administration, Oral | 4 | 2019 | 2340 | 0.27 | Why? |
| Heart Rate | 6 | 2018 | 1527 | 0.27 | Why? |
| Sick Leave | 2 | 2017 | 318 | 0.27 | Why? |
| Heart Valve Diseases | 2 | 2019 | 355 | 0.27 | Why? |
| Primary Prevention | 4 | 2019 | 778 | 0.26 | Why? |
| Lymphoma | 2 | 2018 | 522 | 0.25 | Why? |
| Angioplasty, Balloon, Coronary | 2 | 2019 | 365 | 0.25 | Why? |
| Postoperative Complications | 5 | 2019 | 5861 | 0.25 | Why? |
| Troponin T | 2 | 2018 | 771 | 0.25 | Why? |
| Case-Control Studies | 13 | 2021 | 17671 | 0.25 | Why? |
| Cohort Studies | 25 | 2022 | 36005 | 0.24 | Why? |
| Patient Readmission | 5 | 2019 | 1543 | 0.24 | Why? |
| Comorbidity | 26 | 2021 | 34796 | 0.23 | Why? |
| Prospective Studies | 26 | 2018 | 43301 | 0.23 | Why? |
| Magnetic Resonance Imaging | 8 | 2019 | 6551 | 0.23 | Why? |
| Arrhythmias, Cardiac | 6 | 2019 | 2510 | 0.23 | Why? |
| Vascular Calcification | 2 | 2018 | 396 | 0.22 | Why? |
| Return to Work | 2 | 2017 | 579 | 0.22 | Why? |
| Multidetector Computed Tomography | 3 | 2019 | 307 | 0.22 | Why? |
| Kaplan-Meier Estimate | 10 | 2018 | 4260 | 0.21 | Why? |
| Antihypertensive Agents | 5 | 2020 | 1962 | 0.21 | Why? |
| Stents | 3 | 2017 | 916 | 0.21 | Why? |
| Atherosclerosis | 2 | 2018 | 768 | 0.21 | Why? |
| Pulmonary Disease, Chronic Obstructive | 7 | 2021 | 3832 | 0.20 | Why? |
| Didanosine | 1 | 2019 | 3 | 0.20 | Why? |
| Thymidine | 1 | 2019 | 21 | 0.20 | Why? |
| Anticoagulants | 8 | 2019 | 9563 | 0.20 | Why? |
| Peripheral Arterial Disease | 2 | 2018 | 471 | 0.20 | Why? |
| Diabetes Mellitus, Type 1 | 3 | 2019 | 1969 | 0.20 | Why? |
| 3-Iodobenzylguanidine | 1 | 2018 | 25 | 0.19 | Why? |
| Carpal Tunnel Syndrome | 1 | 2019 | 32 | 0.19 | Why? |
| Penicillin V | 1 | 2018 | 10 | 0.19 | Why? |
| Interatrial Block | 1 | 2018 | 19 | 0.19 | Why? |
| Evoked Potentials, Somatosensory | 1 | 2018 | 40 | 0.19 | Why? |
| Recovery of Function | 3 | 2019 | 2461 | 0.19 | Why? |
| Hyperkalemia | 2 | 2017 | 140 | 0.19 | Why? |
| Population Surveillance | 5 | 2019 | 4967 | 0.19 | Why? |
| Ibuprofen | 1 | 2020 | 156 | 0.18 | Why? |
| Drug Substitution | 2 | 2019 | 385 | 0.18 | Why? |
| Albuminuria | 2 | 2018 | 164 | 0.18 | Why? |
| beta 2-Microglobulin | 1 | 2018 | 102 | 0.18 | Why? |
| Cardiotoxicity | 2 | 2018 | 365 | 0.18 | Why? |
| Chitinase-3-Like Protein 1 | 1 | 2018 | 28 | 0.18 | Why? |
| Electric Injuries | 1 | 2017 | 5 | 0.18 | Why? |
| Ventricular Remodeling | 2 | 2019 | 349 | 0.18 | Why? |
| Diabetic Neuropathies | 1 | 2018 | 64 | 0.18 | Why? |
| Iodine Radioisotopes | 1 | 2018 | 124 | 0.18 | Why? |
| Pre-Excitation Syndromes | 1 | 2017 | 2 | 0.18 | Why? |
| Accessory Atrioventricular Bundle | 1 | 2017 | 2 | 0.18 | Why? |
| Eosinophil Major Basic Protein | 1 | 2017 | 3 | 0.18 | Why? |
| Nursing Assessment | 1 | 2018 | 72 | 0.18 | Why? |
| Glucagon-Like Peptide-1 Receptor | 1 | 2019 | 138 | 0.18 | Why? |
| Pregnancy-Associated Plasma Protein-A | 1 | 2017 | 8 | 0.18 | Why? |
| Dose-Response Relationship, Drug | 5 | 2018 | 3776 | 0.18 | Why? |
| Diabetic Cardiomyopathies | 1 | 2019 | 79 | 0.18 | Why? |
| Administration, Intravenous | 2 | 2019 | 1115 | 0.18 | Why? |
| Antibiotics, Antineoplastic | 1 | 2018 | 128 | 0.17 | Why? |
| Chagas Cardiomyopathy | 1 | 2017 | 50 | 0.17 | Why? |
| Cicatrix | 1 | 2019 | 129 | 0.17 | Why? |
| Accidents | 1 | 2017 | 42 | 0.17 | Why? |
| Glucagon-Like Peptide 1 | 1 | 2018 | 83 | 0.17 | Why? |
| Recurrence | 8 | 2019 | 3675 | 0.17 | Why? |
| alpha-Galactosidase | 1 | 2017 | 32 | 0.17 | Why? |
| Waist Circumference | 1 | 2018 | 199 | 0.17 | Why? |
| Transducers | 1 | 2017 | 65 | 0.17 | Why? |
| Long Term Adverse Effects | 1 | 2018 | 119 | 0.17 | Why? |
| Isoenzymes | 1 | 2017 | 127 | 0.17 | Why? |
| Dipeptides | 1 | 2018 | 106 | 0.17 | Why? |
| Institutionalization | 1 | 2017 | 81 | 0.17 | Why? |
| Gadolinium DTPA | 1 | 2016 | 45 | 0.17 | Why? |
| Enzyme Replacement Therapy | 1 | 2017 | 65 | 0.17 | Why? |
| Lupus Erythematosus, Systemic | 2 | 2018 | 1380 | 0.17 | Why? |
| Amyloidosis | 1 | 2019 | 178 | 0.17 | Why? |
| Adult | 47 | 2021 | 244371 | 0.17 | Why? |
| Biomarkers | 13 | 2020 | 23361 | 0.16 | Why? |
| Coronary Angiography | 8 | 2019 | 2275 | 0.16 | Why? |
| Puerperal Disorders | 1 | 2019 | 151 | 0.16 | Why? |
| Autonomic Nervous System | 1 | 2018 | 148 | 0.16 | Why? |
| Aortic Valve Insufficiency | 1 | 2018 | 136 | 0.16 | Why? |
| Randomized Controlled Trials as Topic | 8 | 2019 | 10649 | 0.16 | Why? |
| Retrospective Studies | 31 | 2021 | 105322 | 0.16 | Why? |
| Medical History Taking | 1 | 2019 | 350 | 0.16 | Why? |
| Contrast Media | 3 | 2019 | 1011 | 0.16 | Why? |
| Platelet Aggregation Inhibitors | 5 | 2019 | 1671 | 0.16 | Why? |
| Obesity, Abdominal | 1 | 2018 | 167 | 0.16 | Why? |
| Brain Ischemia | 3 | 2021 | 2813 | 0.16 | Why? |
| Genetic Loci | 1 | 2018 | 439 | 0.16 | Why? |
| Alkaline Phosphatase | 1 | 2017 | 257 | 0.16 | Why? |
| Cardiomyopathies | 2 | 2019 | 997 | 0.16 | Why? |
| Renal Replacement Therapy | 2 | 2018 | 1530 | 0.16 | Why? |
| Public Sector | 1 | 2018 | 204 | 0.16 | Why? |
| Sodium | 1 | 2018 | 309 | 0.16 | Why? |
| Indoles | 3 | 2013 | 1243 | 0.16 | Why? |
| Diuretics | 4 | 2019 | 326 | 0.16 | Why? |
| Triage | 4 | 2019 | 7151 | 0.16 | Why? |
| Glycopeptides | 1 | 2018 | 199 | 0.16 | Why? |
| Anti-Anxiety Agents | 1 | 2017 | 139 | 0.15 | Why? |
| Streptococcal Infections | 1 | 2019 | 255 | 0.15 | Why? |
| Pregnancy Complications, Cardiovascular | 1 | 2019 | 231 | 0.15 | Why? |
| Benzhydryl Compounds | 1 | 2019 | 240 | 0.15 | Why? |
| Fabry Disease | 1 | 2017 | 106 | 0.15 | Why? |
| Diabetic Nephropathies | 1 | 2019 | 315 | 0.15 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2020 | 1510 | 0.15 | Why? |
| Aspirin | 3 | 2019 | 1043 | 0.15 | Why? |
| Death, Sudden | 1 | 2017 | 160 | 0.15 | Why? |
| Carotid Artery Diseases | 1 | 2018 | 251 | 0.15 | Why? |
| Third-Party Consent | 1 | 2015 | 31 | 0.15 | Why? |
| Prediabetic State | 1 | 2017 | 200 | 0.15 | Why? |
| Propensity Score | 3 | 2019 | 2690 | 0.14 | Why? |
| Ventricular Function, Right | 1 | 2019 | 388 | 0.14 | Why? |
| Tachycardia, Ventricular | 1 | 2018 | 251 | 0.14 | Why? |
| Intraoperative Complications | 1 | 2017 | 221 | 0.14 | Why? |
| Drug Prescriptions | 3 | 2020 | 1062 | 0.14 | Why? |
| Glucosides | 1 | 2019 | 359 | 0.14 | Why? |
| Uric Acid | 1 | 2017 | 285 | 0.14 | Why? |
| Glycated Hemoglobin A | 3 | 2018 | 1316 | 0.14 | Why? |
| Europe | 8 | 2019 | 12702 | 0.14 | Why? |
| Macrolides | 1 | 2018 | 369 | 0.14 | Why? |
| Hemodynamics | 2 | 2020 | 1562 | 0.14 | Why? |
| Proton Pump Inhibitors | 1 | 2019 | 377 | 0.14 | Why? |
| Cardiac Resynchronization Therapy Devices | 3 | 2019 | 64 | 0.13 | Why? |
| Serum Albumin | 1 | 2018 | 571 | 0.13 | Why? |
| Cardiotonic Agents | 2 | 2018 | 418 | 0.13 | Why? |
| Hypoglycemic Agents | 4 | 2019 | 2165 | 0.13 | Why? |
| Sex Factors | 7 | 2019 | 11014 | 0.13 | Why? |
| Adipose Tissue | 1 | 2019 | 612 | 0.13 | Why? |
| Prosthesis-Related Infections | 1 | 2017 | 302 | 0.13 | Why? |
| Time-to-Treatment | 4 | 2018 | 5883 | 0.13 | Why? |
| Pentanoic Acids | 1 | 2012 | 9 | 0.13 | Why? |
| Up-Regulation | 2 | 2018 | 2249 | 0.13 | Why? |
| Hematologic Tests | 1 | 2017 | 521 | 0.12 | Why? |
| Hyperammonemia | 1 | 2012 | 10 | 0.12 | Why? |
| Walking | 1 | 2017 | 442 | 0.12 | Why? |
| Positron-Emission Tomography | 1 | 2018 | 802 | 0.12 | Why? |
| Gastrointestinal Hemorrhage | 1 | 2019 | 669 | 0.12 | Why? |
| Anti-Bacterial Agents | 4 | 2019 | 10083 | 0.12 | Why? |
| Calcium | 1 | 2018 | 708 | 0.12 | Why? |
| Resuscitation | 1 | 2018 | 638 | 0.12 | Why? |
| Mandatory Programs | 1 | 2017 | 291 | 0.12 | Why? |
| Hypertension | 3 | 2020 | 8895 | 0.12 | Why? |
| Radiopharmaceuticals | 1 | 2017 | 763 | 0.12 | Why? |
| Carnitine | 1 | 2012 | 47 | 0.12 | Why? |
| Pyridones | 1 | 2018 | 738 | 0.12 | Why? |
| Emergency Service, Hospital | 6 | 2019 | 14232 | 0.12 | Why? |
| Image Interpretation, Computer-Assisted | 1 | 2019 | 665 | 0.12 | Why? |
| Morbidity | 4 | 2019 | 1426 | 0.12 | Why? |
| Receptors, Adrenergic, beta | 1 | 2011 | 19 | 0.12 | Why? |
| Secondary Prevention | 2 | 2018 | 762 | 0.11 | Why? |
| Acute Disease | 3 | 2020 | 6029 | 0.11 | Why? |
| Antidepressive Agents | 1 | 2017 | 509 | 0.11 | Why? |
| Quality of Life | 5 | 2019 | 9820 | 0.11 | Why? |
| Action Potentials | 3 | 2018 | 368 | 0.11 | Why? |
| Bacteremia | 2 | 2019 | 1372 | 0.11 | Why? |
| Immunization Schedule | 1 | 2019 | 1305 | 0.11 | Why? |
| Metoprolol | 1 | 2011 | 42 | 0.11 | Why? |
| Cardiovascular Agents | 1 | 2017 | 663 | 0.11 | Why? |
| Hemorrhage | 3 | 2018 | 3013 | 0.11 | Why? |
| Heart | 2 | 2018 | 1791 | 0.11 | Why? |
| Electroencephalography | 1 | 2018 | 1242 | 0.11 | Why? |
| Health Status | 3 | 2019 | 3259 | 0.11 | Why? |
| Alanine Transaminase | 1 | 2017 | 1329 | 0.11 | Why? |
| Ventricular Dysfunction, Right | 1 | 2018 | 639 | 0.11 | Why? |
| Age Factors | 11 | 2019 | 21039 | 0.10 | Why? |
| Cardiovascular System | 1 | 2018 | 750 | 0.10 | Why? |
| Insulin | 2 | 2018 | 1316 | 0.10 | Why? |
| Carbazoles | 1 | 2011 | 120 | 0.10 | Why? |
| Data Mining | 1 | 2016 | 767 | 0.10 | Why? |
| Staphylococcal Infections | 1 | 2019 | 1099 | 0.10 | Why? |
| Practice Patterns, Physicians' | 2 | 2018 | 4927 | 0.10 | Why? |
| Emergency Medical Services | 4 | 2019 | 3557 | 0.10 | Why? |
| Thrombolytic Therapy | 2 | 2018 | 2218 | 0.10 | Why? |
| Kidney Diseases | 2 | 2018 | 1434 | 0.10 | Why? |
| Hyponatremia | 1 | 2013 | 371 | 0.10 | Why? |
| Young Adult | 19 | 2020 | 93724 | 0.10 | Why? |
| Cognition | 1 | 2018 | 1394 | 0.10 | Why? |
| Angiotensin II Type 1 Receptor Blockers | 3 | 2019 | 520 | 0.09 | Why? |
| Kidney Failure, Chronic | 2 | 2018 | 3222 | 0.09 | Why? |
| Cross-Sectional Studies | 8 | 2019 | 53120 | 0.09 | Why? |
| Renal Insufficiency, Chronic | 2 | 2021 | 2654 | 0.09 | Why? |
| Non-alcoholic Fatty Liver Disease | 1 | 2018 | 907 | 0.09 | Why? |
| Heart Defects, Congenital | 1 | 2018 | 933 | 0.09 | Why? |
| Cardiology | 3 | 2019 | 2873 | 0.09 | Why? |
| Asymptomatic Diseases | 2 | 2018 | 3444 | 0.09 | Why? |
| Blood Glucose | 3 | 2018 | 3642 | 0.09 | Why? |
| Glomerular Filtration Rate | 3 | 2018 | 1262 | 0.09 | Why? |
| Survival Analysis | 6 | 2018 | 7592 | 0.09 | Why? |
| Homes for the Aged | 1 | 2018 | 1071 | 0.09 | Why? |
| Evidence-Based Medicine | 2 | 2018 | 3228 | 0.09 | Why? |
| Teaching | 1 | 2017 | 1208 | 0.09 | Why? |
| Drug Therapy, Combination | 3 | 2017 | 7268 | 0.09 | Why? |
| General Practitioners | 1 | 2015 | 568 | 0.09 | Why? |
| Drug Combinations | 4 | 2018 | 3852 | 0.09 | Why? |
| Pyrazoles | 1 | 2018 | 1791 | 0.08 | Why? |
| Breast Feeding | 1 | 2018 | 1585 | 0.08 | Why? |
| Logistic Models | 6 | 2019 | 9089 | 0.08 | Why? |
| Body Temperature Regulation | 2 | 2018 | 31 | 0.08 | Why? |
| Lower Extremity | 1 | 2012 | 593 | 0.08 | Why? |
| Severity of Illness Index | 9 | 2021 | 48226 | 0.08 | Why? |
| Muscular Diseases | 1 | 2012 | 392 | 0.08 | Why? |
| Patient Selection | 2 | 2018 | 4560 | 0.08 | Why? |
| Hospital Mortality | 4 | 2021 | 22087 | 0.08 | Why? |
| Prevalence | 8 | 2020 | 25773 | 0.08 | Why? |
| Adolescent | 15 | 2020 | 86841 | 0.08 | Why? |
| Emergencies | 2 | 2019 | 4095 | 0.08 | Why? |
| Tetrahymena | 1 | 1985 | 1 | 0.08 | Why? |
| Methoxsalen | 1 | 1985 | 3 | 0.08 | Why? |
| Growth Inhibitors | 1 | 1985 | 7 | 0.08 | Why? |
| Anti-HIV Agents | 1 | 2019 | 2209 | 0.08 | Why? |
| Employment | 1 | 2017 | 1754 | 0.08 | Why? |
| Diabetes Complications | 1 | 2018 | 2358 | 0.08 | Why? |
| Observer Variation | 2 | 2019 | 622 | 0.08 | Why? |
| Intention to Treat Analysis | 2 | 2018 | 673 | 0.08 | Why? |
| International Normalized Ratio | 2 | 2019 | 300 | 0.08 | Why? |
| Surgical Procedures, Operative | 2 | 2019 | 2662 | 0.08 | Why? |
| Disease Progression | 5 | 2019 | 13580 | 0.08 | Why? |
| Guideline Adherence | 1 | 2019 | 2309 | 0.08 | Why? |
| Hematopoietic Stem Cell Mobilization | 1 | 2006 | 73 | 0.08 | Why? |
| Risk | 4 | 2019 | 5288 | 0.07 | Why? |
| Drug Therapy | 1 | 2008 | 280 | 0.07 | Why? |
| Hyperinsulinism | 1 | 2004 | 27 | 0.07 | Why? |
| DNA Repair | 1 | 1985 | 114 | 0.07 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.07 | Why? |
| Antithrombins | 2 | 2019 | 353 | 0.07 | Why? |
| Patient Discharge | 4 | 2018 | 5696 | 0.07 | Why? |
| Cross-Over Studies | 2 | 2018 | 867 | 0.07 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.07 | Why? |
| Algorithms | 2 | 2019 | 7346 | 0.07 | Why? |
| Wounds and Injuries | 1 | 2017 | 1708 | 0.07 | Why? |
| Digoxin | 2 | 2018 | 68 | 0.07 | Why? |
| Smoking Cessation | 1 | 2013 | 826 | 0.07 | Why? |
| Outpatients | 1 | 2017 | 3417 | 0.07 | Why? |
| Granulocyte Colony-Stimulating Factor | 1 | 2006 | 264 | 0.07 | Why? |
| Chi-Square Distribution | 2 | 2017 | 961 | 0.07 | Why? |
| Plaque, Atherosclerotic | 2 | 2018 | 423 | 0.07 | Why? |
| Nursing Homes | 2 | 2018 | 4155 | 0.07 | Why? |
| Genetic Variation | 1 | 2018 | 3919 | 0.07 | Why? |
| Primary Health Care | 2 | 2019 | 4839 | 0.06 | Why? |
| North America | 2 | 2018 | 1400 | 0.06 | Why? |
| Blood Coagulation | 1 | 2016 | 2768 | 0.06 | Why? |
| Quarantine | 2 | 2021 | 18418 | 0.06 | Why? |
| HIV Infections | 2 | 2019 | 11620 | 0.06 | Why? |
| Communicable Diseases | 1 | 2018 | 2148 | 0.06 | Why? |
| Heart Valve Prosthesis | 2 | 2019 | 533 | 0.06 | Why? |
| Forecasting | 1 | 2017 | 4492 | 0.06 | Why? |
| Intensive Care Units | 2 | 2020 | 29594 | 0.06 | Why? |
| Influenza Vaccines | 1 | 2019 | 2941 | 0.06 | Why? |
| Latin America | 2 | 2018 | 1721 | 0.06 | Why? |
| C-Reactive Protein | 1 | 2019 | 7972 | 0.06 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 1454 | 0.06 | Why? |
| Chronic Disease | 4 | 2019 | 5139 | 0.06 | Why? |
| Liver Diseases | 1 | 2017 | 2698 | 0.06 | Why? |
| Practice Guidelines as Topic | 4 | 2019 | 15421 | 0.06 | Why? |
| Sex Distribution | 2 | 2020 | 2083 | 0.06 | Why? |
| Pulmonary Embolism | 1 | 2021 | 4775 | 0.06 | Why? |
| Communicable Disease Control | 5 | 2022 | 29620 | 0.05 | Why? |
| Neoplasms | 3 | 2019 | 17251 | 0.05 | Why? |
| Calcium Channel Blockers | 2 | 2019 | 367 | 0.05 | Why? |
| Schools | 1 | 2017 | 4187 | 0.05 | Why? |
| History, 20th Century | 2 | 2018 | 1282 | 0.05 | Why? |
| Spirometry | 2 | 2017 | 524 | 0.05 | Why? |
| Societies, Medical | 1 | 2017 | 6907 | 0.05 | Why? |
| Renal Dialysis | 1 | 2018 | 4358 | 0.05 | Why? |
| Pandemics | 10 | 2021 | 389249 | 0.05 | Why? |
| Socioeconomic Factors | 1 | 2018 | 8495 | 0.05 | Why? |
| Research Design | 4 | 2018 | 5830 | 0.05 | Why? |
| Drug Monitoring | 2 | 2019 | 1408 | 0.05 | Why? |
| Coagulase | 1 | 2019 | 44 | 0.05 | Why? |
| Machine Learning | 1 | 2016 | 4395 | 0.05 | Why? |
| History, 21st Century | 2 | 2018 | 1849 | 0.05 | Why? |
| Adrenergic Neurons | 1 | 2018 | 1 | 0.05 | Why? |
| Edema, Cardiac | 1 | 2019 | 33 | 0.05 | Why? |
| Poisson Distribution | 1 | 2020 | 348 | 0.05 | Why? |
| Smoking | 1 | 2013 | 3358 | 0.05 | Why? |
| Europe, Eastern | 1 | 2018 | 88 | 0.05 | Why? |
| Enterococcus faecalis | 1 | 2019 | 126 | 0.05 | Why? |
| Far East | 1 | 2018 | 125 | 0.05 | Why? |
| Asia, Western | 1 | 2018 | 271 | 0.05 | Why? |
| Systole | 1 | 2019 | 252 | 0.05 | Why? |
| Angina, Stable | 1 | 2018 | 45 | 0.05 | Why? |
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2018 | 72 | 0.04 | Why? |
| Mediastinum | 1 | 2018 | 122 | 0.04 | Why? |
| Acute Kidney Injury | 1 | 2018 | 5762 | 0.04 | Why? |
| Mental Disorders | 1 | 2021 | 6742 | 0.04 | Why? |
| Spironolactone | 1 | 2019 | 114 | 0.04 | Why? |
| Preoperative Period | 1 | 2019 | 271 | 0.04 | Why? |
| Confidence Intervals | 1 | 2020 | 744 | 0.04 | Why? |
| Hirudins | 1 | 2018 | 75 | 0.04 | Why? |
| Age Distribution | 2 | 2018 | 3567 | 0.04 | Why? |
| Miniaturization | 1 | 2017 | 29 | 0.04 | Why? |
| Angina, Unstable | 1 | 2018 | 110 | 0.04 | Why? |
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2017 | 49 | 0.04 | Why? |
| Radionuclide Imaging | 1 | 2018 | 184 | 0.04 | Why? |
| Asia, Southeastern | 1 | 2018 | 390 | 0.04 | Why? |
| Walking Speed | 1 | 2017 | 77 | 0.04 | Why? |
| Tissue Survival | 1 | 2016 | 20 | 0.04 | Why? |
| Blood Culture | 1 | 2019 | 308 | 0.04 | Why? |
| Administrative Claims, Healthcare | 1 | 2016 | 124 | 0.04 | Why? |
| Cardiomyopathy, Hypertrophic | 1 | 2019 | 193 | 0.04 | Why? |
| Mood Disorders | 1 | 2021 | 431 | 0.04 | Why? |
| Neprilysin | 1 | 2017 | 112 | 0.04 | Why? |
| Reproducibility of Results | 3 | 2018 | 11304 | 0.04 | Why? |
| Insulin-Like Growth Factor I | 1 | 2017 | 119 | 0.04 | Why? |
| Prostheses and Implants | 1 | 2017 | 116 | 0.04 | Why? |
| Purinergic P2Y Receptor Antagonists | 1 | 2018 | 206 | 0.04 | Why? |
| ROC Curve | 2 | 2019 | 6024 | 0.04 | Why? |
| Prosthesis Implantation | 1 | 2018 | 261 | 0.04 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.04 | Why? |
| Vitamin K | 1 | 2018 | 263 | 0.04 | Why? |
| Vital Capacity | 1 | 2017 | 399 | 0.04 | Why? |
| Delivery of Health Care | 2 | 2021 | 15909 | 0.04 | Why? |
| Blood Flow Velocity | 1 | 2016 | 193 | 0.04 | Why? |
| Endpoint Determination | 1 | 2017 | 344 | 0.04 | Why? |
| Mitral Valve | 1 | 2019 | 342 | 0.04 | Why? |
| Mendelian Randomization Analysis | 1 | 2018 | 317 | 0.04 | Why? |
| Protective Agents | 1 | 2018 | 250 | 0.04 | Why? |
| Lung | 2 | 2017 | 31049 | 0.04 | Why? |
| Heart Atria | 1 | 2018 | 267 | 0.04 | Why? |
| Hospitals, University | 2 | 2018 | 4173 | 0.04 | Why? |
| Microspheres | 1 | 2016 | 261 | 0.04 | Why? |
| Sample Size | 1 | 2017 | 518 | 0.04 | Why? |
| Device Removal | 1 | 2017 | 221 | 0.04 | Why? |
| Survivors | 2 | 2017 | 2619 | 0.04 | Why? |
| Genetic Association Studies | 1 | 2018 | 559 | 0.03 | Why? |
| Regression Analysis | 2 | 2017 | 2484 | 0.03 | Why? |
| Norway | 1 | 2018 | 1004 | 0.03 | Why? |
| Forced Expiratory Volume | 1 | 2017 | 632 | 0.03 | Why? |
| Finland | 1 | 2017 | 671 | 0.03 | Why? |
| Digestive System Diseases | 1 | 2019 | 378 | 0.03 | Why? |
| Educational Status | 1 | 2021 | 1451 | 0.03 | Why? |
| Body Mass Index | 2 | 2018 | 4306 | 0.03 | Why? |
| Longitudinal Studies | 3 | 2019 | 9893 | 0.03 | Why? |
| Factor Xa Inhibitors | 1 | 2019 | 490 | 0.03 | Why? |
| Influenza, Human | 1 | 2019 | 10779 | 0.03 | Why? |
| Analysis of Variance | 1 | 2017 | 950 | 0.03 | Why? |
| Polypharmacy | 1 | 2016 | 347 | 0.03 | Why? |
| Massachusetts | 1 | 2018 | 1279 | 0.03 | Why? |
| Financing, Government | 1 | 2018 | 434 | 0.03 | Why? |
| Patient Reported Outcome Measures | 1 | 2019 | 912 | 0.03 | Why? |
| Microcirculation | 1 | 2017 | 447 | 0.03 | Why? |
| Adverse Drug Reaction Reporting Systems | 1 | 2018 | 694 | 0.03 | Why? |
| Staphylococcus aureus | 1 | 2019 | 844 | 0.03 | Why? |
| Protective Factors | 1 | 2019 | 1720 | 0.03 | Why? |
| Fluorescent Dyes | 1 | 2016 | 536 | 0.03 | Why? |
| Bipolar Disorder | 1 | 2021 | 744 | 0.03 | Why? |
| Patient Outcome Assessment | 1 | 2017 | 707 | 0.03 | Why? |
| Aortic Valve | 1 | 2019 | 664 | 0.03 | Why? |
| Bias | 1 | 2018 | 1109 | 0.03 | Why? |
| Microvessels | 1 | 2017 | 490 | 0.03 | Why? |
| Medical Record Linkage | 1 | 2012 | 58 | 0.03 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2006 | 2426 | 0.03 | Why? |
| Renal Insufficiency | 1 | 2019 | 810 | 0.03 | Why? |
| Pregnancy | 3 | 2019 | 23879 | 0.03 | Why? |
| Cognition Disorders | 1 | 2017 | 574 | 0.03 | Why? |
| Asia | 1 | 2018 | 2399 | 0.03 | Why? |
| Creatinine | 1 | 2018 | 1443 | 0.03 | Why? |
| Netherlands | 1 | 2020 | 3533 | 0.03 | Why? |
| Volunteers | 1 | 2017 | 601 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Cerebrovascular Disorders | 1 | 2019 | 1040 | 0.03 | Why? |
| Respiratory Tract Diseases | 1 | 2019 | 1061 | 0.03 | Why? |
| Schizophrenia | 1 | 2021 | 1018 | 0.03 | Why? |
| Linear Models | 1 | 2017 | 1914 | 0.03 | Why? |
| Liver Function Tests | 1 | 2017 | 1325 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2017 | 2437 | 0.03 | Why? |
| Mental Health | 1 | 2017 | 15770 | 0.03 | Why? |
| Heart-Assist Devices | 1 | 2018 | 812 | 0.03 | Why? |
| Hypotension | 1 | 2013 | 392 | 0.03 | Why? |
| Global Health | 3 | 2019 | 13911 | 0.03 | Why? |
| Infant | 3 | 2020 | 30274 | 0.03 | Why? |
| Health Care Costs | 1 | 2018 | 1007 | 0.02 | Why? |
| Child | 4 | 2021 | 70012 | 0.02 | Why? |
| Pharmacogenetics | 1 | 2011 | 222 | 0.02 | Why? |
| Drug Interactions | 1 | 2016 | 1653 | 0.02 | Why? |
| Early Diagnosis | 1 | 2018 | 2443 | 0.02 | Why? |
| Social Class | 1 | 2017 | 1360 | 0.02 | Why? |
| Terminal Care | 1 | 2019 | 928 | 0.02 | Why? |
| Pain | 1 | 2017 | 1084 | 0.02 | Why? |
| Dogs | 1 | 2016 | 2529 | 0.02 | Why? |
| Sotalol | 1 | 2008 | 9 | 0.02 | Why? |
| Child, Preschool | 3 | 2020 | 36283 | 0.02 | Why? |
| Income | 1 | 2018 | 1564 | 0.02 | Why? |
| Public Policy | 1 | 2021 | 1894 | 0.02 | Why? |
| Program Evaluation | 1 | 2017 | 1929 | 0.02 | Why? |
| Computed Tomography Angiography | 1 | 2018 | 2153 | 0.02 | Why? |
| Recombinant Proteins | 1 | 2018 | 3786 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2017 | 2259 | 0.02 | Why? |
| Amiodarone | 1 | 2008 | 110 | 0.02 | Why? |
| Phenotype | 1 | 2018 | 4037 | 0.02 | Why? |
| Monitoring, Physiologic | 1 | 2018 | 1956 | 0.02 | Why? |
| Equipment Design | 1 | 2017 | 3095 | 0.02 | Why? |
| Chemokine CXCL12 | 1 | 2006 | 74 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2018 | 3788 | 0.02 | Why? |
| Chemokines, CXC | 1 | 2006 | 68 | 0.02 | Why? |
| Coronary Disease | 1 | 2012 | 645 | 0.02 | Why? |
| Health Education | 1 | 2017 | 1539 | 0.02 | Why? |
| Peptides | 1 | 2017 | 2513 | 0.02 | Why? |
| Anti-Arrhythmia Agents | 1 | 2008 | 325 | 0.02 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.02 | Why? |
| Heparin | 1 | 2018 | 2600 | 0.02 | Why? |
| Pilot Projects | 1 | 2016 | 5182 | 0.02 | Why? |
| Polymorphism, Genetic | 1 | 2011 | 1074 | 0.02 | Why? |
| Clinical Competence | 1 | 2018 | 3263 | 0.02 | Why? |
| Liver | 1 | 2018 | 4007 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2018 | 4027 | 0.02 | Why? |
| Respiratory Function Tests | 1 | 2010 | 1755 | 0.02 | Why? |
| Databases, Factual | 1 | 2018 | 6248 | 0.02 | Why? |
| Asthma | 1 | 2021 | 4383 | 0.01 | Why? |
| Myocardial Contraction | 1 | 2002 | 123 | 0.01 | Why? |
| Family | 1 | 2015 | 2909 | 0.01 | Why? |
| Disease Management | 1 | 2018 | 6841 | 0.01 | Why? |
| Length of Stay | 1 | 2018 | 11042 | 0.01 | Why? |
| United States | 2 | 2018 | 46150 | 0.01 | Why? |
| Infant, Newborn | 1 | 2020 | 23105 | 0.01 | Why? |
| Genotype | 1 | 2011 | 4697 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2016 | 10998 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 9706 | 0.01 | Why? |
| United Kingdom | 1 | 2018 | 18046 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.01 | Why? |
| Italy | 1 | 2018 | 38444 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2018 | 25144 | 0.01 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |
| Animals | 1 | 2016 | 78931 | 0.01 | Why? |